Correction to: Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance (Molecular Medicine (2018) 24: 21 DOI: 10.1186/s10020-018-0023-8);Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance

Molecular Medicine

Volumn 24, Issue 1, 2018, Pages

  He, Mingzhu ^a   Bianchi, Marco E ^b   Coleman, Tom R ^a   Tracey, Kevin J ^a   Al Abed, Yousef ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Antagonist; HMGB1; Surface plasmon resonance (SPR); TLR4 signaling; TLR4 MD 2 complex

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN A BOX FRAGMENT; HIGH MOBILITY GROUP B1 PROTEIN B BOX FRAGMENT; ISOPROTEIN; PROTEIN MD 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; HMGB1 PROTEIN, HUMAN; LY96 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BIOLOGICAL FUNCTIONS; DIMERIZATION; KINETICS; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; METABOLISM;

HMGB1 PROTEIN; LYMPHOCYTE ANTIGEN 96; SURFACE PLASMON RESONANCE; TOLL-LIKE RECEPTOR 4;

EID: 85055199838     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.1186/s10020-018-0030-9     Document Type: Erratum

References (38)

1. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139-62.
2. Andrassy M, et al. High-mobility group Box-1 in ischemia-reperfusion injury of the heart. Circulation. 2008;117:3216-26.
3. Bianchi ME, et al. High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol Rev. 2017;280:74-82.
4. Kang R, Livesey KM, Zeh HJ, Lotze MT, Tang D. HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy. 2010;6:1209-11.
5. Kang R, et al. HMGB1 in health and disease. Mol Asp Med. 2014;40:1-116.
6. Kim SJ, Kim HM. Dynamic lipopolysaccharide transfer cascade to TLR4/MD2 complex via LBP and CD14. BMB Rep. 2017;50:55-7.
7. Li J, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med (Manhasset, NY, U. S.). 2003;9:37-45.
8. Li J, et al. Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods. 2004;289:211-23.
9. Maroso M, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med (N Y, NY, U S). 2010;16:413-9.
10. Miyake K. Endotoxin recognition molecules, toll-like receptor 4-MD-2. Semin Immunol. 2004;16:11-6.
11. Muhammad S, et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci. 2008;28:12023-31.
12. Qin S, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med. 2006;203:1637-42.
13. Read CM, Cary PD, Crane-Robinson C, Driscoll PC, Norman DG. Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res. 1993;21:3427-36.
14. Sahu D, Debnath P, Takayama Y, Iwahara J. Redox properties of the A-domain of the HMGB1 protein. FEBS Lett. 2008;582:3973-8.
15. Schiraldi M, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med. 2012;209:551-63.
16. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta, Mol Cell Res. 2000;1498:99-111.
17. Sessa L, Bianchi ME. The evolution of high mobility group box (HMGB) chromatin proteins in multicellular animals. Gene. 2007;387:133-40.
18. Stros M. HMGB proteins: interactions with DNA and chromatin, Biochim. Biophys. Acta, gene Regul. Mech. 2010;1799:101-13.
19. Suda K, et al. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg. 2006;30:1755-62.
20. Ugrinova I, Pasheva E. HMGB1 protein: a therapeutic target inside and outside the cell. Adv Protein Chem Struct Biol. 2017;107:37-76.
21. VanPatten S, Alabed Y. (2017) High mobility group Box-1 (HMGb1) - current wisdom, and advancement as a potential drug target. J Med Chem. https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01136
22. Venereau E, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med. 2012;209:1519-28.
23. Venereau E, et al. HMGB1 as biomarker and drug target. Pharmacol Res. 2016;111:534-44.
24. Visintin A, Iliev DB, Monks BG, Halmen KA, Golenbock DT. MD-2. Immunobiology. 2006;211:437-47.
25. Wang H, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science (Washington, D C). 1999;285:248-51.
26. Wang J, et al. Redox-sensitive structural change in the A-domain of HMGB1 and its implication for the binding to cisplatin modified DNA. Biochem Biophys Res Commun. 2013;441:701-6.
27. Wang Q, Zeng M, Wang W, Tang J. The HMGB1 acidic tail regulates HMGB1 DNA binding specificity by a unique mechanism. Biochem Biophys Res Commun. 2007;360:14-9.
28. Weir HM, et al. Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 1993;12:1311-9.
29. Wu H, et al. High mobility group Box-1: a missing link between diabetes and its complications. Mediat Inflamm. 2016;2016:3896147.
30. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. 2013a;93:865-73.
31. Yang H, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004;101:296-301.
32. Yang H, et al. A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A. 2010;107:11942-7.
33. Yang H, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med (Manhasset, NY, U S). 2012;18:250-9.
34. Yang H, et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med. 2015a;212:5-14.
35. Yang H, et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis. 2015b;6:e1786.
36. Yang Z, et al. TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury. Lab Investig. 2013b;93:792-800.
37. Yuan H, et al. Protective effect of HMGB1 a box on organ injury of acute pancreatitis in mice. Pancreas (Hagerstown, MD, U S). 2009;38:143-8.
38. Zhang C-L, Shu M-G, Qi H-W, Li L-W. Inhibition of tumor angiogenesis by HMGB1 a box peptide. Med Hypotheses. 2008;70:343-5.